These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K; JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664 [TBL] [Abstract][Full Text] [Related]
5. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454 [TBL] [Abstract][Full Text] [Related]
6. BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review. Valentín-Bravo FJ; Pérez-Rodríguez Á; García-Álvarez C; García-Lagarto E; Saornil-Álvarez MA Arq Bras Oftalmol; 2023; 86(5):e20230071. PubMed ID: 35544941 [TBL] [Abstract][Full Text] [Related]
7. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166 [TBL] [Abstract][Full Text] [Related]
8. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
9. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303 [TBL] [Abstract][Full Text] [Related]
10. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile. Larsen AC Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168 [TBL] [Abstract][Full Text] [Related]
11. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240 [TBL] [Abstract][Full Text] [Related]
13. Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature. Chłopek M; Lasota J; Thompson LDR; Szczepaniak M; Kuźniacka A; Hińcza K; Kubicka K; Kaczorowski M; Newford M; Liu Y; Agaimy A; Biernat W; Durzyńska M; Dziuba I; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kato H; Kopczyński J; Michal M; Michal M; Pęksa R; Prochorec-Sobieszek M; Starzyńska A; Takahashi S; Wasąg B; Kowalik A; Miettinen M Mod Pathol; 2022 Nov; 35(11):1609-1617. PubMed ID: 35978013 [TBL] [Abstract][Full Text] [Related]